IPR or EPR? Five Scenarios and a Decision Tree for Post-Grant Patent Challengers in the Life Sciences

The total number of petitions for inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB) has plummeted over the last year, corresponding closely with the USPTO Director’s 2025 changes to the discretionary denial framework for AIA Trial institution decisions….
By: Sterne, Kessler, Goldstein & Fox P.L.L.C.